DDSI showed improved tumor to normal tissue (i.e., prostate versus adipose or muscle) differentiation as compared to using the targeted probe (i.e., PSMA probe) alone in highly PSMA expressing LNCaP tumor xenografts (Fig. 2). This evidence concerns the gene FOLH1 and neoplasm.